2022
DOI: 10.1016/j.diabet.2021.101307
|View full text |Cite
|
Sign up to set email alerts
|

Use of DPP4i reduced odds of clinical deterioration and hyperinflammatory syndrome in COVID-19 patients with type 2 diabetes: Propensity score analysis of a territory-wide cohort in Hong Kong

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
9
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 9 publications
(9 citation statements)
references
References 42 publications
0
9
0
Order By: Relevance
“…Patients with T2DM were captured using the International Classification of Primary Care, Version 2 (ICPC2) code T90 or the International Statistical Classification of Diseases and Related Health Problems, 9th Revision, Clinical Modification (ICD-9-CM) codes 250.x0 or 250.x2. This cohort has been used for studying pharmacoepidemiology of drug treatment for COVID-19 ( 14 ).…”
Section: Methodsmentioning
confidence: 99%
“…Patients with T2DM were captured using the International Classification of Primary Care, Version 2 (ICPC2) code T90 or the International Statistical Classification of Diseases and Related Health Problems, 9th Revision, Clinical Modification (ICD-9-CM) codes 250.x0 or 250.x2. This cohort has been used for studying pharmacoepidemiology of drug treatment for COVID-19 ( 14 ).…”
Section: Methodsmentioning
confidence: 99%
“…Seven studies are included in the analysis of ICU admission and/or mechanical ventilation 8,11,13,18,23,26,29 . The pooled finding indicated DPP‐4i was associated with a statistically significant increase in ICU admission and/or mechanical ventilation in comparison with nonuse of DPP‐4i (RR: 1.24, 95% CI: 1.04, 1.48, p = .02) with substantial heterogeneity ( I 2 = 68%, p = .005) (Figure S9 and S10).…”
Section: Resultsmentioning
confidence: 99%
“…Likewise, it was shown that sitagliptin reduced inflammation and chronic immune cell activation in HIV-infected adults [ 152 ]. In COVID-19 patients with T2DM, the use of DPP4 inhibitors reduced odds of clinical deterioration and hyperinflammatory syndrome [ 153 ]. In a recent meta-analysis addressing the potential impact of DPP4 inhibitors on COVID-19-related death, it was demonstrated that when they were administered in the inpatient setting, DPP4 inhibitors decreased the risk for COVID-19-related death by 50% [ 154 ].…”
Section: Resultsmentioning
confidence: 99%